Alto Neuroscience, Inc. Shareholders' Equity
Alto Neuroscience, Inc. (ANRO) had Shareholders' Equity of $219.25 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-12
- 2026-06-30: Stockholders' Equity Attributable to Parent $219.25M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $243.37M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $151.14M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $111.56M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $219.25M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $243.37M 10-Q · filed 2026-08-12 |
| 2025-12-31 | $151.14M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $111.56M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $123.41M 10-Q · filed 2026-08-12 |
| 2025-03-31 | $139.10M 10-Q · filed 2026-08-12 |
| 2024-12-31 | $151.46M 10-Q · filed 2026-08-12 |
| 2024-09-30 | $165.05M 10-Q · filed 2025-11-12 |
| 2024-06-30 | $179.78M 10-Q · filed 2025-11-12 |
| 2024-03-31 | $193.10M 10-Q · filed 2025-11-12 |
| 2023-12-31 | -$71.67M 10-K · filed 2026-03-16 |
| 2023-09-30 | -$61.10M 10-Q · filed 2024-11-12 |
| 2023-06-30 | -$52.60M 10-Q · filed 2024-11-12 |
| 2023-03-31 | -$45.23M 10-Q · filed 2024-11-12 |
| 2022-12-31 | -$38.41M 10-K · filed 2025-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |